Barclays Maintains Equal-Weight on Pfizer, Lowers Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Equal-Weight rating on Pfizer (NYSE:PFE) but lowered the price target from $40 to $38.
July 11, 2023 | 10:26 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Pfizer but lowered the price target from $40 to $38.
The lowering of the price target by Barclays indicates a potential decrease in Pfizer's stock price in the short term. This is likely to negatively impact the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100